JPWO2023051683A5 - - Google Patents

Info

Publication number
JPWO2023051683A5
JPWO2023051683A5 JP2024520079A JP2024520079A JPWO2023051683A5 JP WO2023051683 A5 JPWO2023051683 A5 JP WO2023051683A5 JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024520079 A JP2024520079 A JP 2024520079A JP WO2023051683 A5 JPWO2023051683 A5 JP WO2023051683A5
Authority
JP
Japan
Prior art keywords
chain variable
seq
variable region
set forth
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538669A (ja
JP2024538669A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/122556 external-priority patent/WO2023051683A1/zh
Publication of JP2024538669A publication Critical patent/JP2024538669A/ja
Publication of JPWO2023051683A5 publication Critical patent/JPWO2023051683A5/ja
Publication of JP2024538669A5 publication Critical patent/JP2024538669A5/ja
Pending legal-status Critical Current

Links

JP2024520079A 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用 Pending JP2024538669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111149114.9 2021-09-29
CN202111149114 2021-09-29
PCT/CN2022/122556 WO2023051683A1 (zh) 2021-09-29 2022-09-29 抗lag3双特异性抗体、药物组合物及用途

Publications (3)

Publication Number Publication Date
JP2024538669A JP2024538669A (ja) 2024-10-23
JPWO2023051683A5 true JPWO2023051683A5 (https=) 2025-10-07
JP2024538669A5 JP2024538669A5 (https=) 2025-10-07

Family

ID=85770153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用
JP2024520079A Pending JP2024538669A (ja) 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用

Country Status (11)

Country Link
US (2) US20250042995A1 (https=)
EP (2) EP4410835A4 (https=)
JP (2) JP2024536881A (https=)
KR (2) KR20240083095A (https=)
CN (1) CN115873123A (https=)
AU (2) AU2022355381A1 (https=)
CA (2) CA3233205A1 (https=)
IL (2) IL311738A (https=)
MX (2) MX2024003936A (https=)
WO (2) WO2023051621A1 (https=)
ZA (2) ZA202403275B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020324185A1 (en) * 2019-08-02 2022-03-03 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-PD-1 antibody and medical use thereof
CA3233205A1 (en) * 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
WO2025232896A1 (zh) * 2024-05-10 2025-11-13 康方汇科(上海)生物有限公司 药物组合及用途
CN120518768B (zh) * 2025-05-30 2025-12-30 中国人民解放军军事科学院军事医学研究院 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201601763SA (en) * 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3099716A1 (en) * 2014-01-28 2016-12-07 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106632674B (zh) 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
KR20180086502A (ko) * 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
SI3468586T1 (sl) * 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
KR20190022632A (ko) * 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
TWI690538B (zh) * 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
EP3630292A2 (en) * 2017-05-24 2020-04-08 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
SMT202300418T1 (it) * 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
KR102666754B1 (ko) * 2018-08-21 2024-05-17 에이비엘바이오 주식회사 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN112079925B (zh) * 2019-06-13 2025-04-25 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
WO2021063201A1 (zh) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
US20230027029A1 (en) * 2019-11-25 2023-01-26 Akeso Biopharma, Inc. Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
BR112022012437A2 (pt) * 2019-12-23 2022-09-20 Macrogenics Inc Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
CN118530341A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的有效性的方法
CA3233205A1 (en) * 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use

Similar Documents

Publication Publication Date Title
JP2021524249A5 (https=)
JPWO2019224717A5 (https=)
JP2017519759A5 (https=)
RU2013136172A (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
WO2013044215A4 (en) Vegf/dll4 binding agents and uses thereof
JP2026041845A5 (https=)
JP2020502233A5 (https=)
JP2025038088A5 (https=)
JPWO2021104302A5 (https=)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2024153733A5 (https=)
JPWO2022042719A5 (https=)
JP2024020436A5 (https=)
JPWO2023051683A5 (https=)
JPWO2021170068A5 (https=)
JPWO2020143720A5 (https=)
JPWO2023051621A5 (https=)
JPWO2023143263A5 (https=)
JPWO2021042019A5 (https=)
RU2025129716A (ru) Биспецифическое антитело, фармацевтическая композиция и применение
RU2024108736A (ru) Биспецифическое антитело к lag3, фармацевтическая композиция и применение
JPWO2023088337A5 (https=)
JPWO2023161943A5 (https=)
JPWO2023186081A5 (https=)
JPWO2023186063A5 (https=)